BNP Paribas Asset Management
SRPT icon

BNP Paribas Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

BNP Paribas Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.5K Sell
1,531
-264
-15% -$4.99K ﹤0.01% 1964
2026
Q1 		$39.1K Buy
1,795
+471
+36% +$9.12K ﹤0.01% 1826
2025
Q4 		$28K Buy
1,324
+485
+58% +$10.2K ﹤0.01% 1844
2025
Q3 		$16K Hold
839
– – ﹤0.01% 1480
2025
Q2 		$14K Buy
+839
New +$35.8K ﹤0.01% 1652
2021
Q1 		– Sell
-156,433
Closed -$26.7M – 872
2020
Q4 		$26.7M Buy
156,433
+18,915
+14% +$2.8M 0.12% 203
2020
Q3 		$19.3M Buy
137,518
+57,852
+73% +$8.79M 0.11% 221
2020
Q2 		$12.8M Sell
79,666
-44,530
-36% -$6.06M 0.09% 259
2020
Q1 		$12.1M Sell
124,196
-5,863
-5% -$670K 0.1% 228
2019
Q4 		$16.8M Buy
130,059
+44,164
+51% +$4.46M 0.11% 228
2019
Q3 		$6.47M Sell
85,895
-14,682
-15% -$1.73M 0.05% 394
2019
Q2 		$15.3M Buy
100,577
+7,716
+8% +$938K 0.12% 221
2019
Q1 		$11.1M Buy
+92,861
New +$11.9M 0.09% 272

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BNP Paribas Asset Management's SRPT Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Sarepta Therapeutics (SRPT) stake by 15% in Q2 2026, selling an estimated $4.99K and leaving 1,531 shares worth $27.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1964.

BNP Paribas Asset Management first reported a position in SRPT in Q1 2019 and has held it in 13 quarters since. The position peaked at $26.7M in Q4 2020. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • BNP Paribas Asset Management held 1,531 shares of Sarepta Therapeutics worth $27.5K as of Q2 2026.
  • BNP Paribas Asset Management sold 264 Sarepta Therapeutics shares in Q2 2026, an estimated $4.99K.
  • Sarepta Therapeutics made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1964 holding.
  • BNP Paribas Asset Management first reported a position in Sarepta Therapeutics in Q1 2019 and has held it in 13 quarters since.
  • BNP Paribas Asset Management's Sarepta Therapeutics position peaked at $26.7M in Q4 2020.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.